new

Get trending papers in your email inbox!

Subscribe

Daily Papers

byAK and the research community

Oct 3

LLaVA-MoLE: Sparse Mixture of LoRA Experts for Mitigating Data Conflicts in Instruction Finetuning MLLMs

Instruction finetuning on a variety of image-text instruction data is the key to obtaining a versatile Multimodal Large Language Model (MLLM), and different configurations of the instruction data can lead to finetuned models with different capabilities. However, we have discovered that data conflicts are inevitable when mixing instruction data from distinct domains, which can result in performance drops for tasks of a specific domain. To address this issue, we propose to apply an efficient Mixture of Experts (MoE) design, which is a sparse Mixture of LoRA Experts (MoLE) for instruction finetuning MLLMs. Within the Transformer layers, we extend the popular Low-Rank Adaption (LoRA) method by creating a set of LoRA experts specifically for the MLP layer, and route each token to the top-1 expert based on a routing function, allowing adaptive choices for tokens from different domains. Since the LoRA experts are sparsely activated, the training and inference cost are kept roughly constant compared to the original LoRA method. By replacing the plain-LoRA of LLaVA-1.5 with our MoE design, our final model is named LLaVA-MoLE. Extensive experiments proved that LLaVA-MoLE effectively mitigates the data conflict issue when mixing multiple distinct instruction datasets with various configurations, and achieves consistent performance gains over the strong plain-LoRA baselines. Most importantly, on the mixed datasets, LLaVA-MoLE can even outperform the plain-LoRA baseline trained with twice the samples.

DrugReasoner: Interpretable Drug Approval Prediction with a Reasoning-augmented Language Model

Drug discovery is a complex and resource-intensive process, making early prediction of approval outcomes critical for optimizing research investments. While classical machine learning and deep learning methods have shown promise in drug approval prediction, their limited interpretability constraints their impact. Here, we present DrugReasoner, a reasoning-based large language model (LLM) built on the LLaMA architecture and fine-tuned with group relative policy optimization (GRPO) to predict the likelihood of small-molecule approval. DrugReasoner integrates molecular descriptors with comparative reasoning against structurally similar approved and unapproved compounds, generating predictions alongside step-by-step rationales and confidence scores. DrugReasoner achieved robust performance with an AUC of 0.732 and an F1 score of 0.729 on the validation set and 0.725 and 0.718 on the test set, respectively. These results outperformed conventional baselines, including logistic regression, support vector machine, and k-nearest neighbors and had competitive performance relative to XGBoost. On an external independent dataset, DrugReasoner outperformed both baseline and the recently developed ChemAP model, achieving an AUC of 0.728 and an F1-score of 0.774, while maintaining high precision and balanced sensitivity, demonstrating robustness in real-world scenarios. These findings demonstrate that DrugReasoner not only delivers competitive predictive accuracy but also enhances transparency through its reasoning outputs, thereby addressing a key bottleneck in AI-assisted drug discovery. This study highlights the potential of reasoning-augmented LLMs as interpretable and effective tools for pharmaceutical decision-making.